The black-and-white checkered floor of the taxi looks a bit like home flooring. The seats are yellow, purple and orange leather, while the pea-green interiors are plastered with daisy stickers. When riding in the cab, passengers can play with plastic swords and a megaphone, or make soap bubbles.
About 140 million women use some type of hormonal contraception, including about 16 million in the United States. But a large Danish study published Wednesday suggests that, like older pills, they still modestly raise the risk of breast cancer, especially with long-term use.
Researchers at the University of Cincinnati (UC) College of Medicine have shown that a new targeted treatment could benefit patients with certain pancreatic tumors by preventing spread of the cancer and protecting their heart from damage—a direct result of the tumor. Higher levels of serotonin among other tumor secretions can cause injury to the valves of the heart over time, leading to cardiac impairment—a condition referred to as cardiac carcinoid disease—in these patients.
Back in 1998, Australian oncologist Jennifer Byrne was among the first to clone a cancer gene that is associated with breast cancer and the type of leukemia most common in children. Two years ago, when Byrne came across mentions of the gene, called TPD52L2, in five papers from separate authors, something didn’t seem quite right.
The Food and Drug Administration has approved a "breakthrough device" that can match cancer patients with individualized treatment regiments with just one test. This device can detect 324 specific genetic mutations and two genomic signatures.
It’s long been one of the most vexing questions for doctors who treat cancer. Why does one patient with a malignant tumor respond well to chemotherapy or to another cancer treatment, and a second patient — with what appears to be the same kind of tumor — doesn’t?